Exploration of the impact of ‘mild phenotypes’ ON median age at death IN the UK CF registry  by Hoo, Z.H. et al.
Respiratory Medicine (2014) 108, 716e721Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate /rmedExploration of the impact of ‘mild
phenotypes’ ON median age at death IN the
UK CF registry
Z.H. Hoo a,b,*, M.J. Wildman a,b, M.D. Teare ba Adult Cystic Fibrosis Unit, CF Office, Brearley Outpatient, Northern General Hospital, Sheffield S5
7AU, United Kingdom
b School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, United KingdomReceived 23 November 2013; accepted 19 February 2014
Available online 12 March 2014KEYWORDS
Cystic fibrosis (MeSH
term);
Survival analysis
(MeSH term);
Registries (MeSH
term);
Epidemiology (MeSH
term)* Corresponding author. Adult Cystic
7AU, United Kingdom. Tel.: þ44 114 2
E-mail address: zhhoo@doctors.or
http://dx.doi.org/10.1016/j.rmed.20
0954-6111/Crown Copyright ª 2014 PSummary
Background: The widespread availability of genetic testing allowing the identification of
“milder” individuals with CF coincided with improvements in CF life expectancy but the rela-
tive contribution of case mix to that improved survival is uncertain.
Methods: Patients in the UK CF registry were divided into ’mild phenotype’ defined as pancre-
atic sufficient and ’typical CF’ defined as pancreatic insufficient. Distributions of age at death
were compared with ManneWhitney test. Temporal trends in incidence and prevalence were
described. JonckheereeTerpstra test was used to compare the trend for median age at death
from 2007 to 2010.
Results: Patients with ‘mild phenotype’ had significantly higher age at death (32 years, inter-
quartile range 14 years versus 27 years, interquartile range 29 years; ManneWhitney test p-
value Z 0.026). The proportion of patients with ’mild phenotype’ appeared to be increasing
(0.128 in 2007, 0.144 in 2010). The trend for increasing age at death (from 25 years in 2007
to 29 years in 2010, JonckheereeTerpstra test p-valueZ 0.012) was independent of the ‘mild
phenotype’ patients.
Conclusion: The impact of mild phenotypes on the improvement in the median age at death
among people with CF was trivial.
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The life expectancy of cystic fibrosis (CF) patients has
improved significantly over the last 50 years, with a median
age at death of around 6 months in 1959 increasing to
around 27 years in 2008 [1]. This trend of improvement
continues even within the last decade: according to the CF
Trust 2010 Annual data report, the median age at death was
24 years in 2007 and 29 years in 2010 [2]. It is important to
note that this improvement outstrips the survival
improvement of the general population [3].
It has been suggested that some of the survival
improvement may be driven by widespread genetic testing
identifying rarer cystic fibrosis transmembrane conduc-
tance regulator (CFTR) mutations among older, ‘atypical’
patients which skews existing survival data [4e8].
A study on CF patients aged more than 40 years showed
that these patients are more likely to be pancreatic suffi-
cient, have well preserved lung function and BMI; and less
likely to have a DF508 mutation [9]. These differences are
particularly marked for patients with a late diagnosis of CF
[10]. Studies have also demonstrated that CF patients with
‘mild genotypes’ (class IV and V CTFR mutations) tend to
have mild clinical manifestations, are often pancreatic
sufficient and have low mortality [11].
In 1982, only 2.8% of the patients enrolled in the Cystic
Fibrosis Foundation (CFF) registry in the US received the
diagnosis after the age at 18 years [1]. By 2002 the preva-
lence of ‘late diagnosis’ had risen to 4.1% of the population
(and 9.9% of all the new diagnoses for 2002) [12]. In
Northern Ireland, the number of individuals diagnosed with
CF in adulthood has increased from 12 in 1990e1999 to 40 in
2000e2009 [13]. The significant increase in the proportion
of CF patients with normal FEV1 in adulthood has also
coincided with increased case finding of ‘atypical’ CF pa-
tients [14].
To date there has been no exploration of the impact of
the increased prevalence of mild phenotypes on the overall
survival reported in registry data. In this study, we have
analysed the UK CF registry data with following hypothesis:
the increase in patients with ‘mild phenotype’ who have
better survival compared to ‘typical CF’ patients has
significantly contributed to the improvement in median age
at death between 2007 and 2010.
Methods
This is a cohort analysis based on all the data available from
the UK CF registry from 2007 to 2010. All patients in the UK
CF registry are included, with no exclusion criteria.
Data
Data of all CF patients within the UK CF registry who were
born before 2011 and were alive at some point from 2000 to
2010 were obtained. In 2007, the CF Trust implemented the
new CF registry using the web-based technology of Port CF.
Only the data for 2007 to 2010 had been through a thorough
data checking process and included a single “annual review”
encounter for all patients. Therefore, to ensure validity, the
analyses for trends were restricted to the 2007 to 2010 data.Statistical analysis
All statistical analyses were performed with SPSS version 18
(SPSS Inc., Chicago, IL, USA), with a p-value of <0.05
considered to be statistically significant. All statistical tests
were 2-sided.
Data exploration were performed to determine the
extent of missing data and to compare the descriptive re-
sults with the CF Trust 2010 Annual data report [2] to check
that the data cleaning processes were performed
appropriately.
Each patient within theUKCF registry has a unique patient
ID (CFF_ID). If multiple entries with regards to pancreatic
supplement were present, the latest entry was used.
Pancreatic sufficiency was used as a marker of ‘mild pheno-
type’ because this group of patients have been demonstrated
to have milder disease and better survival compared to CF
patients who are pancreatic insufficient [9,15,16]. Patients
were defined as pancreatic insufficient (i.e. ‘typical CF’) if
they are on pancreatic enzyme replacement therapy. In the
UK, pancreatic status is established through clinical assess-
ment and measurement of faecal elastase. The level faecal
elastase is not collected routinely and the UK CF registry uses
the prescription of pancreatic enzyme replacement therapy
as an indicator of pancreatic status.
The distributions of age at death from 2007 to 2010 for
patients with ‘mild phenotype’ (i.e. pancreatic sufficient)
versus ‘typical CF’ patients (i.e. pancreatic insufficient)
was compared using ManneWhitney U Test.
Descriptive statistics were provided for the incidence
and prevalence for ‘mild phenotypes’ patients and ‘typical
CF’ patients from 2007 to 2010.
The JonckheereeTerpstra (Jonckheere’s trend) test was
used to determine the evidence of trend of overall, ‘mild
phenotype’ and ‘typical CF’ for increasing age at death
from 2007 to 2010 [17].
Results
There were in total 10516 patients registered within the UK
CF registry who were alive at some point from 2000 to 2010,
with details in Table 1. Mortality data were also compared
against the national death data [18] to determine the
extent of missing death data.
Survival of ‘mild phenotype’ versus ‘typical CF’
patients
As detailed in Fig. 1, there was a significant difference
between deaths of patients who are pancreatic sufficient
(n Z 18) versus pancreatic insufficient (n Z 440) with
median age at death 32 years (IQR 14 years) versus 27 years
(IQR 29 years), Mann Whitney p-value Z 0.026.
Temporal trend of incidence and prevalence from
2007 to 2010
The overall prevalence of people with CF is increasing while
the overall incidence is decreasing, suggesting that CF pa-
tients were living longer.
Figure 1 Box plots for age at death for patients with
pancreatic insufficiency (‘typical CF’) vs pancreatic sufficient
(‘mild phenotype’). Figure 1 showed in detail the differences in
age at death from 2007 to 2010 for patients with pancreatic
insufficiency (‘typical CF’) vs pancreatic sufficient (‘mild
phenotype’) using box plots and ManneWhitney test for sta-
tistical comparison.
Table 1 Number of patients, missing data and data
exploration.
Total number of patients 10516
Pancreatic insufficient
(‘typical CF’)
8169 (77.7%)
Pancreatic sufficient
(‘mild’ phenotype)
1235 (11.7%)
Pancreatic status missing 1112 (10.6%)
Incidence from 2007 to 2010 1371
Pancreatic insufficient (% of
incidence from 2007 to 2010)
526 (38.4%)
Pancreatic sufficient (% of
incidence from 2007 to 2010)
257 (18.7%)
Pancreatic status missing
(% of incidence from 2007 to 2010)
588 (42.9%)
Number of deaths from 2007 to 2010 474
Pancreatic insufficient (% of deaths
from 2007 to 2010)
440 (92.8%)
Pancreatic sufficient (% of deaths
from 2007 to 2010)
18 (3.8%)
Pancreatic status missing
(% of deaths from 2007 to 2010)
16 (3.4%)
Total deaths from 2000 to 2010 1218
Pancreatic insufficient (% of total
deaths from 2000 to 2010)
1022 (83.9%)
Pancreatic sufficient (% of total
deaths from 2000 to 2010)
20 (1.6%)
Pancreatic status missing
(% of total deaths from 2000 to 2010)
176 (14.4%)
Mortality data
from the UK
CF registry
UK total CF
deaths [18]
Number of deaths in 2007 112 (21 missing) 133
Number of deaths in 2008 116 (6 missing) 122
Number of deaths in 2009 143 (4 missing) 147
Number of deaths in 2010 103
Table 1 showed in detail the total number of patients, the
extent of data missing within the UK CF registry and also missing
mortality data from the UK CF registry. The extent of missing
mortality data is diminishing and it is expected that the data
will be even more robust with the implementation of a National
Tariff for Cystic Fibrosis (Payment by Results, PbR).
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pancreatic sufficient (‘mild phenotype’) had increased
steadily, supporting the impression that there has been
increased case finding of patients with ‘mild phenotypes’.
The incidence trend may not support this conclusion, but
the incidence trend needs to be interpreted with extreme
caution due to the extent of missing data as detailed in
Tables 1 and 2.
Median age at death from 2007 to 2010
As shown in Table 3, the trend of increasing age at death for
all people with CF is statistically significant with the
JonckheereeTerpstra test (standard JeT statistic Z 2.52,
p-value Z 0.012).
The trend for median age at death for patients who were
pancreatic insufficient (‘typical CF’ patients) also improvedconsistently from 2007 to 2010 (standard J-T
statistic Z 2.73, p-value Z 0.006).
On the other hand, there was no obvious trend in the
median age at death for pancreatic sufficient patients
(‘mild phenotype’ patients), with standard J-T
statisticZ 0.48, p-valueZ 0.634. This may well be due to
the small number of deaths in this group.
Discussions
These analyses of the UK CF registry database from 2007 to
2010 found that patients who are pancreatic sufficient
(‘mild phenotype’) have significantly higher median age at
death compared to their counterparts who can be consid-
ered to have ‘typical CF’. The data suggest a steadily
increasing proportion of patients with who are pancreatic
sufficient (‘mild phenotype’) within the UK CF registry. The
statistically significant trend of improvement for age at
death among CF patients from 2007 to 2010 is due to the
increasing age at death among patients with ‘typical CF’
(patients with pancreatic insufficiency), rather than due to
increased case finding of patients with ‘mild phenotypes’
(pancreatic sufficient).
It is encouraging for ‘typical CF’ patients that the trend
of improvement for age at death is not driven by increased
case findings of patients with ‘mild phenotypes’. Along with
the findings of another study that the median age of death
among people with CF is improving more rapidly than that
of the general population [3], this should engender hope
among the CF population.
CF care delivery in the UK
In the UK, CF care is delivered by 24 specialist adult centres
and 25 specialist paediatric centres [2]. All the centres are
Table 2 Temporal trends of prevalence and incidence from 2007 to 2010.
2007 2008 2009 2010
Overall prevalence 8756 9004 9220 9385
Prevalence of pancreatic sufficient 1079 1159 1192 1220
Prevalence proportion of ‘pancreatic sufficient’ 0.128 0.135 0.139 0.144
Prevalence of pancreatic insufficient 7319 7417 7356 7241
Missing data on pancreatic status 358 428 672 924
Overall incidencea 383 356 331 301
Incidence of pancreatic sufficient 103 82 38 34
Incidence proportion of pancreatic sufficient 0.269 0.230 0.115 0.113
Incidence of pancreatic insufficient 259 202 47 18
Table 2 showed in detail the temporal trend in incidence and prevalence from 2007 to 2010 for CF patients registered within the UK CF
registry. The results for incidence based on pancreatic status are adversely affected by missing data (42.9% of the incidence data
between 2007 and 2010 did not mention whether patients were on pancreatic supplement or not), hence any trend in incidence pro-
portion should be treated with caution. The prevalence trend is however more reliable with only 10.6% missing data.
a CF registry identifies these patients as new diagnosis rather than simply patients who had not previously been in the database.
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peer reviews to support and facilitate improvements in the
delivery of specialist CF care. As of 2011, 43% of the pa-
tients in the UK CF Registry are looked after in paediatric
centres while 57% were looked after in adult centres [2].
The policy of the Department of Health is for CF care to be
centrally commissioned and centrally funded. If someone is
known to have CF, they will only receive the CF care tariff if
they are cared for in an accredited specialist CF centre.
Therefore, almost all patients diagnosedwithCF in theUKare
followed up by specialist centres. The extremely small (and
diminishing) numbers of deaths occurring outside specialist
centres [18] presented in Table 1 indicate that most CF pa-
tients are indeed followed up by specialist centres.
Median age at death as a marker of survival
The median age at death has been criticised as ‘a limited
surrogate’ for survival, since it does not take into account
the alive population that is under observation [7]. In a
condition such as CF whereby survival is consistently
improving, the median age at death invariably un-
derestimates the median survival of the population [19].
Despite the lag, temporal trend in median age at death
tends to follow the trend in survival [19]. Using currentTable 3 Median age at death and number of deaths from 2007
2007
Overall median age at death, years
(inter-quartile range)
25.0 (10)
Median age at death for pancreatic sufficient
(inter-quartile range)
27.5 (range Z
Median age at death for pancreatic insufficient
(inter-quartile range)
25.0 (10)
Total number of death 112
Number of death for pancreatic sufficient 2
Number of death for pancreatic insufficient 105
Table 3 showed in detail the median age at death according to patieavailable lifetable techniques to estimate the median
predicted survival among the CF population is also prob-
lematic, since it assumes that current mortality rates
reflect future rates and hence remain constant over the
population’s lifetime [20].
The median age at death has therefore been proposed as
a simple to calculate, yet robust indirect marker of survival
[21]. Median is also more immune to the effect of outliers
by being responsive only to the scores above and below it
instead of the actual values [22]. Therefore, the median
age at death remains ‘uncontaminated’ by the small in-
crease in the numbers of ‘mild phenotype’ patients. By
2010, only 14.4% of all CF patients in the UK were pancre-
atic sufficient.
Epidemiological trend
Although the number of pancreatic sufficient (‘mild pheno-
type’) patients within the UK CF registry remained small,
there is a signal of increasing proportion of these patients
which is in keeping with the findings from the US [12].
This is on the background of falling incidence of CF
diagnosis. In particular, other registries analysis demon-
strated a decline in incidence (or live birth prevalence) of
CF, especially with diagnosis by newborn screeningto 2010.
2008 2009 2010 JonckheereeTerpstra
test p-value
26.5 (14) 27.0 (15) 29.0 (16) 0.012
7) 43.0 (35) 48.5 (31) 25.0 (18) 0.634
26.0 (13) 27.0 (14) 30.0 (15) 0.006
116 143 103
5 6 5
108 133 94
nt category and also the number of deaths in similar a format.
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patients within the European Union (EU) may stabilise due
to smaller family size and prenatal screening [26].
However, the most noticeable trend in the incidence and
prevalence analyses is actually the consistent growth of the
total number of patients registered within the CF registry
by about 200 patients per year from 2007 to 2010. This
trend is consistent with the previous mortality and survival
analyses among the UK and US CF populations [6,7].
While improved survival will increase the CF pop-
ulations, the data in this study (with the diminishing missing
data) demonstrated that more complete records of CF pa-
tients also contributed.Effects of patients who are pancreatic sufficient as
a unique group
Themedian age at death for CF patients was higher in the US
compared to theUK [16]. Therewere also a higher proportion
of very old (more than 70 years) CF patients in the US
compared the UK [18]. These very old patients are likely to
have ‘mild phenotypes’, which may be explained by wider
genetic testing in the US. It was suggested this could
contribute to the higher median age at death in the US [18].
However, given that the number of very old patients
remained small in the US [17] and the robustness of median
age at death to outlier effect by a small group of patients,
it is unlikely that differences in the median age at death
between the UK and the US can be entirely explained by the
differences in the proportion of patients with ‘mild phe-
notypes’ or very old patients.
It would nonetheless be informative to compare the
differences in the median age at death across the different
national registries concentrating only on ‘typical CF’ pa-
tients. If there are significant differences due to the out-
lying effects of patients with ‘mild phenotypes’, then
perhaps this group of patients should be considered sepa-
rately when reporting the median age at death in the
various national CF registries.
It would also be informative to compare the differences
in causes of death among ‘typical CF’ and ‘mild phenotype’
patients. If a difference is found, this will add further
weight to the argument that patients with ‘mild pheno-
types’ should be considered separately when reporting the
median age at death in CF registries.
Several registry analyses have considered the ‘mild
phenotype’ patients separately. A US CF Foundation Na-
tional Patient Registry mortality analysis included four
subgroup analyses among patients to reduce the effect of
selection bias and performed mortality analysis according
to different age groups which demonstrated that the
improvement in mortality is most significant among pa-
tients aged 2e15 years old, which is unlikely to be from
dilution by patients with mild phenotypes [7]. A study
comparing CF survival within EU versus non-EU nations
performed additional analysis among patients with homo-
zygous DF508 to avoid possible bias from a higher propor-
tion of milder genotypes within EU countries [27].
It should be noted that there are constraints to using
pancreatic status in defining a sub-group of CF patients,
since patients who are initially pancreatic sufficient mayeventually become pancreatic insufficient [28]. This con-
version may follow after several episodes of pancreatitis
among people with CF who were pancreatic sufficient.
There is the argument that only pancreatic status
around the age of diagnosis should be used to determine
disease severity. Someone who is pancreatic insufficient
because of poor CFTR function is different from someone
who became pancreatic insufficient due to repeated epi-
sodes of pancreatitis [28]. However, the detail of pancre-
atic status around the age of diagnosis is not available for
everyone within the UK CF registry. Therefore, for consis-
tency while performing this analysis, the most up-to-date
pancreatic status was used.
Other strengths and weaknesses of this study:
trade-off between validity of analysis versus
statistical power
By only using the robust data from 2007 to 2010, the extent
of missing data was minimised and accuracy of analysis was
increased. While this analysis cannot completely exclude
the effect of reduced measurement bias from improved CF
patients registration [8], this effect is minimised by only
using the data from 2007 to 2010 and using median age at
death as a marker of survival.
This however came at a cost of reduced data richness to
accurately elucidate a temporal trend in both the epide-
miological and mortality pattern across time. The smaller
amount of available data also made multivariate analysis to
adjust for patients’ gender and presence of CF related
diabetes (both of which are markers of poorer prognosis
[29,30]) difficult to perform.
Conclusion
The trend of improvement for the age at death among the
UK CF population from 2007 to 2010 achieved statistical
significance. This represented the improvement in the age
at death among ‘typical’ CF patients who are pancreatic
insufficient.
During the same period, there was an increasing pro-
portion of patients who are pancreatic sufficient (‘mild
phenotype’). This group of patients have a significantly
higher age at death. However, due to their small number,
their median age at death have no impact upon the overall
figure in the UK.
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